收费全文 | 352篇 |
免费 | 10篇 |
财政金融 | 65篇 |
工业经济 | 16篇 |
计划管理 | 76篇 |
经济学 | 77篇 |
综合类 | 4篇 |
运输经济 | 3篇 |
旅游经济 | 6篇 |
贸易经济 | 58篇 |
农业经济 | 21篇 |
经济概况 | 34篇 |
邮电经济 | 2篇 |
2023年 | 2篇 |
2022年 | 2篇 |
2021年 | 4篇 |
2020年 | 9篇 |
2019年 | 15篇 |
2018年 | 8篇 |
2017年 | 9篇 |
2016年 | 6篇 |
2015年 | 6篇 |
2014年 | 6篇 |
2013年 | 43篇 |
2012年 | 13篇 |
2011年 | 18篇 |
2010年 | 9篇 |
2009年 | 14篇 |
2008年 | 21篇 |
2007年 | 16篇 |
2006年 | 10篇 |
2005年 | 11篇 |
2004年 | 11篇 |
2003年 | 11篇 |
2002年 | 8篇 |
2001年 | 17篇 |
2000年 | 5篇 |
1999年 | 8篇 |
1998年 | 9篇 |
1997年 | 6篇 |
1996年 | 11篇 |
1995年 | 7篇 |
1994年 | 3篇 |
1993年 | 5篇 |
1992年 | 5篇 |
1991年 | 5篇 |
1990年 | 3篇 |
1989年 | 4篇 |
1988年 | 3篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 1篇 |
1984年 | 3篇 |
1983年 | 3篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1976年 | 1篇 |
1970年 | 1篇 |
Objective: To assess the 3-year budget impact for a typical US health plan following availability of everolimus for treatment of GI and lung NETs.
Methods An economic model was developed that considered two perspectives: an entire health plan and a pharmacy budget. The total budget impact included costs of drug therapies, administration, hospitalizations, physician visits, monitoring, and adverse events (AEs). The pharmacy model only considered drug costs.
Results: In a US health plan with 1 million members, the model estimated 66 patients with well-differentiated, non-functional, and advanced or metastatic GI NETs and 20 with lung NETs undergoing treatment each year. Total budget impact in the first through third year after FDA approval ranged from $0.0568–$0.1443 per member per month (PMPM) for GI NETs and from $0.0181–$0.0355 PMPM for lung NETs. The total budget impact was lower than the pharmacy budget impact because it included cost offsets from administration and AE management for everolimus compared with alternative therapies (e.g. chemotherapies).
Limitations: Because GI and lung NETs are rare diseases with limited published data, several assumptions were made that may influence interpretation of results.
Conclusions: The budget impact for everolimus was minimal in this rare disease area with a high unmet need, largely due to low disease prevalence. These results should be considered in the context of significant clinical benefits potentially provided by everolimus, including significantly longer progression-free survival (PFS) for advanced GI and lung NET patients. 相似文献
![点击此处可从《Agricultural Economics》网站下载免费的PDF全文](/ch/ext_images/free.gif)